Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug896 | Camostat Mesilate Wiki | 0.67 |
| drug3325 | Positive Peer Journaling (PPJ) Wiki | 0.50 |
| drug3960 | Sham iTBS to the dlPFC Wiki | 0.50 |
Navigate: Correlations HPO
There are 4 clinical trials
Cigarette smoking constitutes the greatest preventable cause of mortality and morbidity in the US. The most critical period for long term success of smoking cessation appears to be in the first 7 days after the quit date. A metaanalysis of 3 pharmacotherapy trials revealed that abstinence during the first 7 days was the strongest predictor of 6 month outcomes (n=1649; Odds ratio: 1.4, P <0.0001; Ashare et al. 2013). Prodigious relapse rates during this first week of smoking cessation are likely due to behavioral and neurobiological factors that contribute to high cue-associated craving and low executive control over smoking. The long term goal of the research is to develop evidence-based transcranial magnetic stimulation protocols to facilitate abstinence during this critical period.
Description: The effect of real vs. sham iTBS to the left DLPFC vs. real vs. sham cTBS to the left MPFC as a tool to modulate the brain response to cigarette cravings will be assessed by comparing the brain activity in the executive circuit and limbic circuit before and after TMS. Participants will receive an MRI brain scan before their first TMS treatment, and at the end of their 10th days of TMS. At each MRI scan, participants will be subjected to a cigarette craving "cue" task within the scanner where elevated brain activity (BOLD signal) will be measured using an fMRI sequence. During each scan, they will see pictures of cigarette cues, neutral cues, and blurred images. The task is meant to induce craving and see how the brain responds to these craving cues.
Measure: Neuroimaging outcomes: changes in drug cue reactivity as specified by changes in BOLD signal Time: Through study completion, an average of 8 weeksDescription: Participants will be asked to choose between two conditions in which varying amounts and delays to behavioral outcomes (e.g., $50 now or $100 later) are presented. We will use magnitudes of $100 and $1000 which are the most thoroughly documented among the literature. Across consecutive choices, the delay to the larger outcome will be titrated until reaching the participant's indifference delay (i.e., the delay at which s/he equally values both options). This indifference delay indexes individual participants' rates of delay discounting. Monetary delay discounting has been documented to be predictive to treatment success for smokers.
Measure: Changes in Delayed Discounting Cognitive Behavioral Task Time: Through study completion, an average of 8 weeksDescription: This 10-item questionnaire assesses cigarette craving. Participants will be asked to rate from 1 (strongly disagree) to 100 (strongly agree) their agreement with several statements (e.g., "I have a desire for a cigarette right now," and "Nothing would be better than smoking a cigarette right now."). Factor analyses support two factors: one that reflects a strong desire and intention to smoke and one that reflects relief from negative affect associated with an urgent desire to smoke.
Measure: Questionnaire on Smoking Urges administered daily both pre/post TMS to measure craving Time: Through study completion, an average of 8 weeksDescription: The hypothetical purchase task (HPT), a validated measure for cigarette demand, will assess cigarette purchases at various price conditions. Participants will hypothetically purchase quantities of cigarettes to use over a 24-hour period across ascending prices (e.g., $0, 0.12, $0.25, $0.50, $1.00, and $2.00 per cigarette). The HPT has been shown to be predictive of treatment outcomes. It will measure how participants value cigarettes throughout the course of the study visits.
Measure: Hypothetical Purchase Task to measure tobacco product value and sensitivity Time: Through study completion, an average of 8 weeksDescription: Changes in cigarette use as detected by quantitative cotinine urine screens collected at visits 1, 6, 10, and all follow-ups
Measure: Biochemical assessment of tobacco use via quantitative urine screens to detect cotenine level Time: Through study completion, an average of 8 weeksDescription: This self-reported tobacco product use interview asks participants to retrospectively estimate the number of tobacco products they've used each day for the past 30 days or since the previous assessment, whichever is fewer.
Measure: Self- report assessment of tobacco use through Timeline Follow-Back (TLFB) Interview Time: Through study completion, an average of 8 weeksDescription: Breath CO provides an accurate measure of recent exposure to CO, including from smoking combustible tobacco products (95). The CO measurement will be used to determine recency of smoking.
Measure: Biochemical assessment of recent tobacco use via breath Carbon Monoxide (CO) sample Time: Through study completion, an average of 8 weeksThe current context of the Covid-19 health crisis leads to an over-solicitation of health systems, with hospital staff in the front line. These personnel are undergoing high levels of stress, an alteration of their life rhythm, but also of their health status and quality of life at work. In addition, night work, through the disruption of circadian rhythms, has consequences on physical and mental health. The more frequent worsening of the condition of certain patients at night increases the burden and responsibilities of night staff. Increasing the use of psychoactive substances (SPAs) can become a solution for managing stress, work rhythms, sleep disorders and their consequences. This self-medication behaviour is not without risks, neither for staff nor for patients. The ALADDIN study is a project made up of 2 waves of questionnaires - one during and the other after the Covid "hospital" crisis - filled in by the hospital night staff of AP-HP. This project will assess the impact of the Covid-19 epidemic on the quality of work life, mental health disorders, post-traumatic stress and substance use of hospital night staff. The main objectives of this study is to evaluate the prevalence of psychoactive substance consumption among the night shift healthcare workers of the AP-HP and to describe the participants' quality of working life. Methods The study is prospective study using an online self-completed questionnaire. The questionnaire was elaborated on the basis of the validated scales ASSIST (Alcohol, Smoking, and Substance Involvement Screening Test), AUDIT-C (Alcohol Use Disorder Test, shortened version) and HAD (for anxiety and depression) and on qualitative interviews conducted among care staff working the night shift. The questionnaire will be completed at t0 (baseline) and 18 months after. This study will provide data on the consumption psychoactive substances by night hospital workers adn their quality of working life. It will also allow us to compare their consumption with the general population, and to describe the risk factors influencing the consumption.
Description: Prevalence in APHP health workers of psychoactive substance consumption during the Covid 19 outbreak
Measure: Substance use prevalence Time: at T0 month : baselineDescription: Evaluation of the quality of working life during the Covid 19 outbreak using a validated scale
Measure: Quality of working life scale Time: at T0 month : baselineDescription: Identify the preferences for intervention to improve the quality of life or change the addictive risk of night hospital staff at the APHP. Preferences for intervention methods and ranking of the least preferred.
Measure: Intervention preference Time: at T0 monthDescription: Describe the risk factors associated with the consumption of psychoactive substances (PAS). Logistic or fish linear regression depending on the type of variable taken into account.
Measure: Psychoactive substance consumption and associated factors Time: at T0 monthDescription: Evaluate the impact of substance use on quality of life at work Principal component analysis and classification to see if there are consumer groups for the night and / or day population. Method for taking into account missing, unused or invalid data
Measure: Impact of substance consumption on quality of life at work Time: at T0 monthDescription: Describe the risk factors associated with tobacco use among night hospital workers,
Measure: Risk factors associated with tobacco use Time: at T0 monthDescription: Evaluate the impact of sleep quality on the quality of working life and perceived health of night staff
Measure: Impact of sleep quality on quality of working life and perceived health Time: at T0 monthDescription: Describe the links between QWL and sleep, anxiety, depressive syndromes, and workplace upheaval.
Measure: Impact of anxiety and depressive symptoms on sleep and QWL. Time: at T0 monthDescription: Describe the links between anxiety/depressive syndromes and workplace disruption, sleep, and the Covid epidemic.
Measure: Impact of sleep and workplace upheaval on anxiety and depressives symptoms Time: at T monthDescription: Comparison between the baseline score and prevalences and the score and prevalences 18 months after
Measure: Modification of quality of working life score and psychoactive substances consumption prevalences Time: T18 monthsDescription: Analysis of the relation between declared change and evolution of the quality of life score
Measure: Comparison of modification of quality of life score and declared quality of life modification after 18 month Time: T18 monthsThe current containment linked to COVID-19 will have consequences for people suffering from addiction and there is a risk of overdoses when the containment ends. So the investigators hypothesize that this health crisis is an opportunity to develop risk reduction and access to care for vulnerable people who lives with an addiction. The main objective of this study is to describe the changes in the psychoactive substances consumption during the containment in people suffering from addiction. The secondary objectives are to describe the evolution at 1 month from the end of the containment of problematic consumption and the level of access to care of these users
Description: measurement of the difference in drugs consumption caused by containment (delta)
Measure: Evolution of consumption Time: 1 dayDescription: measurement of the difference in drugs consumption caused by containment (delta)
Measure: Evolution of consumption Time: 1 month after confinmantDescription: number of drug users referred to care (%)
Measure: health care access Time: 1 dayDescription: number of drug users referred to care (%)
Measure: health care access Time: 1 month after confinmantThe main objective of this study is to pilot test the Positive Peer Journaling (PPJ) intervention and its feasibility and acceptability. A second objective is to compare individuals assigned to PPJ to individuals in a treatment as usual control group.
Description: Score on the "Satisfaction with Life" scale. This scale has 5 items assessed on a 7 point Likert-type response format. Scores range from 5 to 35 with higher scores representing higher satisfaction with life.
Measure: Satisfaction with Life Time: 9 weeksDescription: Score on a single item, "In general, I am happy with my recovery." This item uses an 11 point scale ranging from 0 to 11. Higher scores represent higher happiness with recovery.
Measure: Happiness with recovery Time: 9 weeksDescription: Score on a single item, "I will do whatever it takes to recover from my addiction." This item uses an 11 point scale ranging from 0-11. Higher scores represent greater commitment to sobriety.
Measure: Commitment to sobriety Time: 9 weeksAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on December 13, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports